HC Wainwright Issues Optimistic Estimate for PCRX Earnings

Key Points

• HC Wainwright raised its Q4 2026 EPS estimate for Pacira BioSciences to $0.68 from $0.64 and maintained a “Buy” rating with a $38 price target.
• Pacira recently reported quarterly EPS of $0.73, beating the $0.65 consensus estimate, while revenue of $192.4 million increased 6.2% year over year and exceeded expectations.
• Analyst sentiment is mixed overall: the stock has a consensus “Hold” rating and $29.80 target price, despite upgrades from some firms and institutional investors owning 99.73% of shares.

Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Investment analysts at HC Wainwright lifted their Q4 2026 EPS estimates for Pacira BioSciences in a research note issued on Wednesday, August 5th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of $0.68 per share for the quarter, up from their previous forecast of $0.64. HC Wainwright currently has a "Buy" rating and a $38.00 target price on the stock. The consensus estimate for Pacira BioSciences' current full-year earnings is $1.94 per share.

A number of other research firms have also recently weighed in on PCRX. Weiss Ratings upgraded shares of Pacira BioSciences from a "sell (d)" rating to a "sell (d+)" rating in a report on Wednesday, May 20th. Royal Bank Of Canada upped their price target on shares of Pacira BioSciences from $24.00 to $25.00 and gave the company a "sector perform" rating in a research note on Wednesday, August 5th. Wall Street Zen raised shares of Pacira BioSciences from a "buy" rating to a "strong-buy" rating in a report on Saturday. Finally, Needham & Company LLC lifted their price objective on shares of Pacira BioSciences from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $29.80.

Pacira BioSciences Stock Performance

NASDAQ PCRX opened at $24.43 on Tuesday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.94 and a current ratio of 5.04. Pacira BioSciences has a fifty-two week low of $18.80 and a fifty-two week high of $27.66. The company has a market cap of $973.78 million, a P/E ratio of 69.80 and a beta of 0.27. The business's 50 day moving average price is $24.72 and its 200-day moving average price is $23.47.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.08. Pacira BioSciences had a return on equity of 9.68% and a net margin of 1.96%.The company had revenue of $192.40 million for the quarter, compared to the consensus estimate of $191.06 million. During the same quarter last year, the company earned $0.74 EPS. The firm's quarterly revenue was up 6.2% on a year-over-year basis.

Insider Transactions at Pacira BioSciences

In other news, SVP Lauren Riker sold 6,115 shares of the company's stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $23.50, for a total transaction of $143,702.50. Following the completion of the sale, the senior vice president owned 62,284 shares of the company's stock, valued at $1,463,674. This represents a 8.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.40% of the company's stock.

Institutional Trading of Pacira BioSciences

Several hedge funds have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Pacira BioSciences by 5,900.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,500 shares of the company's stock valued at $39,000 after buying an additional 1,475 shares during the last quarter. Kestra Advisory Services LLC acquired a new position in shares of Pacira BioSciences during the fourth quarter worth about $48,000. Eurizon Capital SGR S.p.A. acquired a new position in Pacira BioSciences during the 4th quarter worth approximately $51,000. Global Retirement Partners LLC purchased a new stake in shares of Pacira BioSciences during the 2nd quarter worth $51,000. Finally, Meeder Asset Management Inc. purchased a new position in Pacira BioSciences in the first quarter valued at about $46,000. Institutional investors and hedge funds own 99.73% of the company's stock.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company's flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source